This has a lot to do with PRO 140. PRO 140 is not getting enrollment support due to current HAART 96% efficacy, long term, with huge Patient exposure years and currently lower discontinuation rates. The demand for PRO 140 will be muted by SOC and current HAART success in multiple areas. Read the previous two articles. N=1127 and supported by WHO (World Health Organization) and NIH (National Institute of Health) I did not write the articles...just relaying reliable and valid sources....
News 
Market Data 
Discover 
